Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares Electric Vehicles and Future Mobility (KARS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

KraneShares Electric Vehicles and Future MobilityTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

KraneShares Electric Vehicles and Future Mobility vs Recursion Pharmaceuticals Inc — how do they compare? KraneShares Electric Vehicles and Future Mobility trades at $27.56 (market cap $72.36M), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 29.6× KraneShares Electric Vehicles and Future Mobility's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares Electric Vehicles and Future Mobility for 46 Days and Recursion Pharmaceuticals Inc for 22 Days on average.

KARSRXRX
Market Cap
$72.36M$2.14B
Volume
5,03430,789,535
Sector
Sector/ThematicHealth
52-Week High
$38.01$6.79
52-Week Low
$27.25$2.84
Typical Hold Time
46 Days22 Days
Enterprise Value
—$1.66B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares Electric Vehicles and Future Mobility

No Aura AI signal available yet.

Recursion Pharmaceuticals Inc

RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.

The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KARS

No sentiment data available yet.

RXRX
8% Buy92% Sell
Avg holding period · 22 Days

About KraneShares Electric Vehicles and Future Mobility

KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.

Read more on KARS →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX →